Community Health Officer informs students of flu and cold season
Hawaii reps call for hearing on missile alerts after false alarm
The Terrifying Reason You Should Never Try to Hold in a Sneeze
Wal-Mart Wants To Battle Opioid Abuse Crisis With New Disposal Service
Unique Rainbow-Dinosaur Fossil Found in China, Appears like Humming Birds
FBR & Co Lowers Argos Therapeutics Inc (ARGS) Price Target to $1.20
21 April 2017, 03:00 | Todd Saunders
The short ratio in the company's stock is documented at 2.08 and the short float is around of 8.97%. The stock, after opening at $0.64, hit $0.6 through the close by scoring 53.39%. The updated stock price target implies a possible upside of 0.97% based on the company's previous stock price. Its last month's stock price volatility remained 11.59% which for the week approaches 17.35%.
Analysts on average have given a price target of $1.6 to Argos Therapeutics, Inc. (ARGS) to Buy by settling a price target of $18 on 4/19/16. There is no concrete way to calculate a price target. The company's market capitalization is $16.13 million. Finally, Zacks Investment Research cut Argos Therapeutics from a buy rating to a hold rating in a research report on Tuesday, February 7th. (ARGS) to Buy with a price target of $21.
The share price of Argos Therapeutics Inc (ARGS) was up +7.73% during the last trading session, with a day high of 0.41. The stock as of last trading session moved 26.16% up from its 52 week low and was -97.20% behind its 52 week high.
Analysts give OAS a mean recommendation of 2.10. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company.
A number of analysts have commented on ARGS shares.
Strawberries may cut breast cancer risk
After five weeks on a strawberry-boosted diet, the mice showed no sign of progressing cancer spread and their tumours had shrunk. The researchers also said that the concentration of phenolic compounds can vary greatly between varieties of strawberry.
Canada refutes U.S. claims of unfair dairy trade
Walker said he also planned to talk privately with Trump about the issue during his stop in Wisconsin on Tuesday. That leaves plenty of time for Trump to adopt MacNaughton's "glass is half full" outlook on Canada-U.S. trade.
Argos Therapeutics Inc had its " rating reiterated by analysts at Stifel Nicolaus. (NASDAQ:SSH), its shares were trading at $0.91 a retreat of $-0.44, on the trading floor. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus the company showed an Earnings Surprise of -2.9 Percent. The Return on Investment (ROI) ratio of Argos Therapeutics, Inc.
Toll Brothers, Inc. (NYSE:TOL) ended its day at $37.09 with the rising stream of 0.71% and its total traded volume was 1.72 million shares less than the average volume.
Argos Therapeutics (NDAQ:ARGS) had its target price lowered to $1.20 by FBR Capital in a report issued 04/19/2017. It's now trading about -95.54% below its 52-week high. The firm has a 50 day moving average of $0.78 and a 200 day moving average of $3.62.
A moving average (MA) is a trend-following or lagging indicator because it is based on past prices.
Stock is now moving with a negative distance from the 200 day simple moving average of approximately -85.54%, and has a poor year to date (YTD) performance of -87.76% which means the stock is constantly subtracting to its value from the previous fiscal year end price. The Monthly and Yearly performances are -29.42 percent and -94.39 percent respectively. The Lower end of the earnings estimate is $-0.39, while the higher end of the earnings estimate is $-0.26. (NASDAQ:ARGS). ROIC (Return on Invested Capital) is a financial metric that can be used to measure how efficient a company is at allocating controlled capital into profitable investments. The company's net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin. This ranking was created by James O'Shaughnessy using six different valuation ratios including price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings, and shareholder yield. The stock is showing its Operating Margin of 0 percent.
CORRECTED - Chipmaker Qualcomm's revenue falls 9.6 percent
Qualcomm's non-GAAP revenue excludes a almost $1 billion reduction of revenue related to an arbitration agreement with BlackBerry. In the long run, Arcuri said Qualcomm "appears to have a strong case, and Apple's record in winning similar litigation is poor".
What to know about Air Defense Identification Zones
According to a USA official, a pair of Russian bombers flew close to Alaska, they came within 35 nautical miles of the coastline. Two Russian TU-95 bombers came within 100 miles south of Kodiak Island last Monday.
Cavs' J.R. Smith questionable for Game 3 with sore hamstring
Stephenson and coach Nate McMillan say there were no hurt feelings. "We lost our poise and wasn't calm during that third quarter". And while he's determined to play and committed to the Cavs, Smith's mind is never far from his daughter. "And that was big".
Turkish PM warns opposition against street protests
The referendum has no "democratic legitimacy", HDP spokesman and lawmaker Osman Baydemir told reporters in Ankara. Opposition CHP head Kemal Kilicdaroglu accused the electoral board of bias and of favoring the governing party.
Trump says shooting in Paris looks like 'terrorist attack'
ET) when a vehicle stopped at 102 Champs-Elysees in front of a police van, Interior Ministry spokesman Pierre Henry Brandet said. Although an anti-terror probe has been opened, other reports said the shooting could have been an attempt at an armed robbery.